Furthermore, experimental models combining PDE5 inhibitors with vaccine-based or checkpoint-based immunotherapies have reported improved antitumor responses in pancreatic ductal adenocarcinoma and hepatocellular carcinoma (14, 15). This evidence concerns the gene PDE5A and hepatocellular carcinoma.